AC Immune SA (NASDAQ:ACIU) reported favorable interim Phase 1 clinical trial results for ACI-19764, an orally administered drug designed to target the NLRP3 inflammasome.
The clinical-stage biopharmaceutical company primarily focuses on developing targeted therapies for neurodegenerative conditions.
The European study evaluates the drug’s safety, tolerability, and pharmacokinetics in healthy volunteers.
Early findings indicate that ACI-19764 remains safe and well-tolerated across single and multiple ascending dose groups.
The company tested doses up to 20mg daily, noting a serum half-life exceeding 30 hours. Researchers observed no serious adverse events or treatment withdrawals during this period.
